Tudor Investment Corp ET AL Makes New Investment in AbCellera Biologics Inc. $ABCL

Key Points

• Tudor Investment Corp bought a new stake of 730,122 shares in AbCellera (NASDAQ:ABCL), valued at about $3.67 million, representing roughly 0.24% ownership per its latest SEC filing.
• Bank of America dramatically increased its position, adding 2,193,939 shares in the quarter (a 977.8% rise) and now holds 2,418,304 shares worth about $12.16 million; institutional investors collectively own 61.42% of the stock.
• AbCellera reported a quarterly EPS loss of ($0.03) that beat estimates of ($0.18) and revenue of $44.85 million versus an expected $6.31 million; the company has a ~$1.02 billion market cap and a consensus analyst rating of Hold with an average target of $7.75.

Tudor Investment Corp ET AL purchased a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 730,122 shares of the company's stock, valued at approximately $3,673,000. Tudor Investment Corp ET AL owned about 0.24% of AbCellera Biologics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ABCL. Advisory Services Network LLC purchased a new position in shares of AbCellera Biologics in the 3rd quarter worth $132,000. Caxton Associates LLP purchased a new stake in AbCellera Biologics during the third quarter valued at about $1,798,000. Voleon Capital Management LP acquired a new stake in AbCellera Biologics during the third quarter worth about $56,000. Sherbrooke Park Advisers LLC purchased a new position in shares of AbCellera Biologics in the 3rd quarter worth about $87,000. Finally, Bank of America Corp DE raised its holdings in shares of AbCellera Biologics by 977.8% in the 3rd quarter. Bank of America Corp DE now owns 2,418,304 shares of the company's stock worth $12,164,000 after purchasing an additional 2,193,939 shares during the period. 61.42% of the stock is currently owned by institutional investors and hedge funds.

AbCellera Biologics Price Performance

NASDAQ:ABCL opened at $3.35 on Friday. The business's 50-day moving average is $3.52 and its two-hundred day moving average is $4.11. The firm has a market capitalization of $1.02 billion, a PE ratio of -6.84 and a beta of 0.84. AbCellera Biologics Inc. has a 12 month low of $1.89 and a 12 month high of $6.51.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. AbCellera Biologics had a negative return on equity of 15.05% and a negative net margin of 198.37%.The company had revenue of $44.85 million during the quarter, compared to the consensus estimate of $6.31 million. Equities analysts anticipate that AbCellera Biologics Inc. will post -0.59 EPS for the current year.

Analyst Upgrades and Downgrades

ABCL has been the subject of a number of research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of AbCellera Biologics in a report on Wednesday, January 21st. Wall Street Zen raised shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a research report on Saturday, February 14th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AbCellera Biologics presently has a consensus rating of "Hold" and an average target price of $7.75.

AbCellera Biologics Profile

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

Want to see what other hedge funds are holding ABCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.